Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ask Vendit Off-Topic Questions -- Ignore unavailable to you. Want to Upgrade?

To: Vendit™ who wrote (4064)	1/20/2005 6:50:35 PM
From: Walkingshadow	Read Replies (2) \| Respond to of 8752

I'll have to look further.... I remember last month reading some stuff about the company, but can't remember. Here's something I found with a quick scan from that time, probably this is what caught my attention. I like to follow the cancer trials wherever possible, those stocks can make huge moves.... as you well know, from your "best trading day ever" story !!! 22-Dec-04 13:47 ET YM BioSciences: Color on TheraCIM data - Merriman (YMI) 2.61 +0.11 : Merriman notes that yesterday YMI announced preliminary results from a randomized phase II trial conducted by its licensor in Cuba, and says TheraCIM may be better than equivalent to Erbitux. Notably, there was no evidence of skin rash, which has been seen with all other EGF receptor-blocking agents and has previously been assumed to be inseparable from efficacy. While survival data will be needed in order to compare these impressive tumor response results with those of Erbitux radiation therapy in head and neck cancer, firm believes that increasing visibility of the co's valuable pipeline could catalyze gains in the stock over the next 12-18 months toward $8-$12, a valuation more closely in-line with peers. 21-Dec-04 07:41 ET In Play YM BioSciences announces Phase II results of TheraCim h-R3 combined w/ radiation in head, neck cancer (YMI) 2.32 : Of 130 patients, those who received the combination had a 90.6% complete response vs. 51.5% in the radiation-alone group. "Complete Response" is defined as the elimination of tumor at the primary site, locoregional lymph nodes and distant metastases. TheraCIM h-R3 was administered intravenously at a dose of 100 mg/person once a week for eight weeks beginning on the first day of radiotherapy. There was no evidence of the acneiform rash, a common side effect in similar treatments. T